Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

96 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Catalase, a remarkable enzyme: targeting the oldest antioxidant enzyme to find a new cancer treatment approach.
Glorieux C, Calderon PB. Glorieux C, et al. Biol Chem. 2017 Sep 26;398(10):1095-1108. doi: 10.1515/hsz-2017-0131. Biol Chem. 2017. PMID: 28384098 Review.
Evaluation of Potential Mechanisms Controlling the Catalase Expression in Breast Cancer Cells.
Glorieux C, Sandoval JM, Dejeans N, Nonckreman S, Bahloula K, Poirel HA, Calderon PB. Glorieux C, et al. Oxid Med Cell Longev. 2018 Jan 28;2018:5351967. doi: 10.1155/2018/5351967. eCollection 2018. Oxid Med Cell Longev. 2018. PMID: 29535798 Free PMC article.
Chromatin remodeling regulates catalase expression during cancer cells adaptation to chronic oxidative stress.
Glorieux C, Sandoval JM, Fattaccioli A, Dejeans N, Garbe JC, Dieu M, Verrax J, Renard P, Huang P, Calderon PB. Glorieux C, et al. Free Radic Biol Med. 2016 Oct;99:436-450. doi: 10.1016/j.freeradbiomed.2016.08.031. Epub 2016 Aug 31. Free Radic Biol Med. 2016. PMID: 27591797
Regulation of catalase expression in healthy and cancerous cells.
Glorieux C, Zamocky M, Sandoval JM, Verrax J, Calderon PB. Glorieux C, et al. Free Radic Biol Med. 2015 Oct;87:84-97. doi: 10.1016/j.freeradbiomed.2015.06.017. Epub 2015 Jun 25. Free Radic Biol Med. 2015. PMID: 26117330 Review.
Catalase expression in MCF-7 breast cancer cells is mainly controlled by PI3K/Akt/mTor signaling pathway.
Glorieux C, Auquier J, Dejeans N, Sid B, Demoulin JB, Bertrand L, Verrax J, Calderon PB. Glorieux C, et al. Biochem Pharmacol. 2014 May 15;89(2):217-23. doi: 10.1016/j.bcp.2014.02.025. Epub 2014 Mar 11. Biochem Pharmacol. 2014. PMID: 24630930
Catalase overexpression in mammary cancer cells leads to a less aggressive phenotype and an altered response to chemotherapy.
Glorieux C, Dejeans N, Sid B, Beck R, Calderon PB, Verrax J. Glorieux C, et al. Biochem Pharmacol. 2011 Nov 15;82(10):1384-90. doi: 10.1016/j.bcp.2011.06.007. Epub 2011 Jun 13. Biochem Pharmacol. 2011. PMID: 21689642
Redox-active quinones and ascorbate: an innovative cancer therapy that exploits the vulnerability of cancer cells to oxidative stress.
Verrax J, Beck R, Dejeans N, Glorieux C, Sid B, Pedrosa RC, Benites J, Vásquez D, Valderrama JA, Calderon PB. Verrax J, et al. Among authors: glorieux c. Anticancer Agents Med Chem. 2011 Feb;11(2):213-21. doi: 10.2174/187152011795255902. Anticancer Agents Med Chem. 2011. PMID: 21395522 Review.
Molecular chaperone Hsp90 as a target for oxidant-based anticancer therapies.
Beck R, Dejeans N, Glorieux C, Pedrosa RC, Vásquez D, Valderrama JA, Calderon PB, Verrax J. Beck R, et al. Among authors: glorieux c. Curr Med Chem. 2011;18(18):2816-25. doi: 10.2174/092986711796011256. Curr Med Chem. 2011. PMID: 21568884 Review.
Regulation of CD137 expression through K-Ras signaling in pancreatic cancer cells.
Glorieux C, Huang P. Glorieux C, et al. Cancer Commun (Lond). 2019 Jul 9;39(1):41. doi: 10.1186/s40880-019-0386-4. Cancer Commun (Lond). 2019. PMID: 31288851 Free PMC article.
Chemotherapy induces tumor immune evasion by upregulation of programmed cell death ligand 1 expression in bone marrow stromal cells.
Yang M, Liu P, Wang K, Glorieux C, Hu Y, Wen S, Jiang W, Huang P. Yang M, et al. Among authors: glorieux c. Mol Oncol. 2017 Apr;11(4):358-372. doi: 10.1002/1878-0261.12032. Epub 2017 Feb 20. Mol Oncol. 2017. PMID: 28218497 Free PMC article.
96 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page